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Advancing Pediatric Antibacterial Drug Development: 
A Critical Need to Reinvent our Approach
Gary J. Noel,1 Sumathi Nambiar,2 and John Bradley,3 for the Clinical Trials Transformation Initiative’s Pediatric Antibiotic Drug Development Program
1Johnson & Johnson, Raritan, New Jersey; 2US Food and Drug Administration, Silver Spring, Maryland; and 3University of California, San Diego, Rady Children’s Hospital, 
California
The Clinical Trials Transformation Initiative convened with several groups in the pediatric antibacterial drug development commu-
nity with the goal of identifying challenges and recommending ways to improve current practice. Attention to 5 major areas hold the 
promise of making new antibiotics available for use in children as soon as possible after they are approved for use in adults.
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The emergence of antimicrobial resistance to many important 
bacterial pathogens has renewed interest in developing new 
antibacterial drugs. The process for advancing these critically 
needed therapies to the clinic is expected to start with studies 
that involve adults and will occur well before studies are con-
ducted in children. Although requirements for assessment 
of the safety and efficacy of new drugs in children as defined 
in US law [1] are being met, recent experience indicated that 
the completion of pediatric trials necessary for US Food and 
Drug Administration (FDA) approval and updated labeling for 
a pediatric indication for a new antibacterial drug often takes 
5 to 10 years after approval for use in adults [2]. Because chil-
dren are at risk of infection from the same drug-resistant bac-
teria as adults, it is likely that once a new antibacterial drug is 
approved for adults, using that drug in children will be consid-
ered by many clinicians even before the safety and efficacy of it 
in children have been established [3–5]. This use can result in 
suboptimal treatment of infants and children and underscores 
an urgent need for the process for developing and evaluating 
antibacterial drugs for children to be improved and accelerated.
To address this challenge, the Clinical Trials Transformation 
Initiative, a public–private partnership with funding from the 
FDA, convened experts to identify factors that contribute to 
delays in the completion of pediatric antibacterial drug trials and 
to offer recommendations for improvements. Through extensive 
discussions and investigations by stakeholders representing the 
FDA, drug developers, academia, clinical research networks, 
parents, and care providers, barriers to pediatric antibacterial 
drug trials were identified, and suggestions for addressing these 
barriers were developed [6]. The key consensus elements that 
resulted from this effort belong to 5 major areas: early plan-
ning, protocol development and trial design, informed consent, 
healthcare provider engagement, and reporting and labeling.
DRUG-DEVELOPMENT PLANNING
Planning for pediatric trials should begin as early as possible 
in the drug development process. To ensure optimal alignment 
with global regulatory expectations and the medical needs of 
children, company sponsors and other funders should consider 
early collaboration with regulators. They also should seek input 
from the pediatric infectious diseases community, the neonatal 
community, and parents with the goal of planning a develop-
ment program that addresses all stakeholder needs.
In nearly all instances, early data regarding the pharmacoki-
netics, safety, and efficacy of a new antibacterial drug in adults 
will provide sufficient information to enable clinicians to out-
line a rational plan for its development in children. Unnecessary 
delays in beginning a pediatric program can be avoided by 
starting pharmacokinetic studies that involve children once 
data from early-phase adult trials provide preliminary evidence 
of efficacy with no concerning safety signals.
PROTOCOL DESIGN AND DEVELOPMENT
Successful completion of a pediatric trial depends on the active 
engagement of parents, children, nurses, physicians, study 
coordinators, sponsors, and regulators. The goal of broader 
stakeholder engagement in the development of a trial protocol 
should be to design that trial to generate sufficient information 
to establish safety and efficacy for a new antibacterial drug while 
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considering the unique needs and risks inherent in managing 
sick neonates, infants, and children.
In constructing a pediatric drug development program, con-
sideration should be given to how data generated in adult trials 
can be extrapolated to inform conclusions about antibacterial 
drug efficacy in children. For many bacterial diseases, especially 
in older children and adolescents, the pathophysiology of the 
disease in children will be sufficiently comparable to that in 
adults to allow for extrapolation of a drug’s efficacy from adults 
to children. In these circumstances, trials focused on defining 
the dose to match the drug exposure in adults and safety in chil-
dren might suffice to support pediatric labeling [7].
INFORMED CONSENT
The chaotic disruption of family life that accompanies the diagno-
sis of a serious acute bacterial infection in a child needs to be rec-
ognized and addressed when helping a family navigate the process 
of informed consent for a trial. Whenever possible, this process 
should be led and managed by personnel who have established a 
relationship with and are trusted by the child and family, includ-
ing hospital and nursing staff or the child’s primary care provider. 
Discussion with families who might have participated in clinical 
trials already or been involved in protocol design will help investi-
gators to better anticipate the needs and concerns of families and 
children who are new to clinical trials. Throughout the child’s par-
ticipation in the trial, families should be encouraged to continue 
discussion related to their child’s safety and well-being.
HEALTHCARE PROVIDER ENGAGEMENT
Involving the child’s usual healthcare providers in planning pro-
grams, designing protocols, and serving as trial investigators is 
critical for ensuring that children’s medical needs are met and tri-
als are conducted efficiently. Although it might not be possible for 
a child’s primary care provider to serve as a trial site investigator, 
the involvement of a trial site’s healthcare providers in trial plan-
ning can be very effective in connecting trial sponsors to those 
physicians and nurses who best understand the medical needs of 
children in their community. By making this connection, it might 
be possible for healthcare providers to prepare children and their 
families for the possibility of participating in a clinical trial and 
to serve as a resource of information to those who choose to be 
involved in such a trial. The time and energy needed to establish 
relationships based on trust and respect between the sponsors 
and healthcare providers/investigators are often not accounted 
for sufficiently in the development process. Providers must have 
a transparent view of the goals and objectives of new antibacte-
rial drug-development programs. They also must be committed 
to generating the most accurate and useful data from children 
who are receiving experimental drugs so that study findings can 
inform both regulatory agencies and the healthcare providers 
who will eventually prescribe those drugs.
Likewise, a sponsor’s knowledge of an investigator’s experi-
ence and available clinical infrastructure is critical for ensuring 
that investigators have access to appropriate resources to con-
duct a trial in accordance with good clinical practice. Experience 
in ensuring the safe conduct of trials that involve children indi-
cates that pediatric trials will likely require substantially greater 
resources than are typically needed for adult trials. This must be 
considered when planning for the resources needed to complete 
this work and will require a detailed and realistic discussion of 
these resources among sponsors, clinical research organiza-
tions, and research sites. A sponsor’s or clinical research orga-
nization’s budget for a pediatric trial must reflect the likelihood 
that more resources per subject enrolled will be needed to com-
plete it than is needed to complete a trial that involves adults, 
and consideration that substantial variation across sites might 
exist on the basis of available infrastructure and local healthcare 
costs should be given. Providing inadequate funding is not in 
the best interests of any stakeholders and can lead to substantial 
delay and costs that exceed that which would have been needed 
if the funding was adequate initially.
REPORTING AND LABELING
Rapid widespread dissemination of findings from pediatric 
trials is needed to ensure that practitioners caring for children 
understand the benefits and risks of using new antibacterial 
drugs. Publication and presentation of information at national 
and international forums should occur as soon as a study has 
been completed. Public discussion of this information can be 
helpful in identifying important issues that should be addressed 
as the development program progresses. In addition, labeling 
related to children can be updated and expanded as important 
pharmacokinetic, safety, and efficacy data for different pediatric 
age groups are generated.
Recommendations in each of these areas reflect a single 
theme: the imperative for collaboration across all groups and 
individuals who have a stake in the development of new anti-
bacterial drugs for use in children. Although collaboration 
undoubtedly is important in other therapeutic areas, the urgent 
need to understand optimal dosing, safety, and efficacy of new 
antibacterial agents in infants and children makes it an espe-
cially important issue for those engaged in antibacterial drug 
development. It is clear that new antibacterial therapies must 
be developed to address the medical needs of our youngest 
patients. Being well prepared to collaborate in bringing these 
advances to children is the responsibility of and challenge to 
everyone concerned about the health of children.
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